|
|
Office Locations:
|
47 North Main Street
Akron, OH 44308
Phone: 330-572-7544
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Austen BioInnovation Institute in Akron--a unique collaboration of Akron Children's Hospital, Akron General Health System, Northeast Ohio Medical University, Summa Health System, The University of Akron and The John S. and James L. Knight Foundation--is focused on patient-centered innovation and commercialization at the intersection of biomaterials and medicine. The institute is focused on being a global leader in discovering, developing and commercializing biomaterials solutions for patients with orthopaedic and wound healing problems, nationally distinct in improving health outcomes with a focus on the medically underserved, and recognized for the use of simulation technologies to improve the education of the healthcare team. More than 30 Northeast Ohio high school students participated in the 2017 BioInnovation Academy, a program that encourages students from around the region to explore solutions to real-life health and medical problems.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
